Immune response to myeloma antigens vary with disease stage
2015
University of Heidelberg, Heidelberg, Germany
Multiple myeloma (MM) is a rarely curable malignant disease caused by the accumulation of cells in the bone marrow which displaces the normal composition of blood cells. In the present study, the researchers have assessed the concomitant expression of two antigens in myeloma cells purified from patients. Further, the researchers analyzed ex vivo the antigen-specific T-cell responses against these antigens using patients cells at different stages of the disease. They showed that specific T-cell responses in myeloma are triggered by antigen expression at an early stage but diminish and get suppressed with increasing tumor load during the evolution of the disease which underlines the necessity to take into account disease progression when developing immunotherapy.
Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myeloma
Michael Hundemer
Added on: 09-14-2021
[1] https://clincancerres.aacrjournals.org/content/early/2015/03/09/1078-0432.CCR-14-1618.article-info?versioned=true[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
